0SUTE1504001
CARCINOMA
DE
II CURSO
Laboratórios Pfizer, Lda.
Sociedade Comercial por Quotas
Lagoas Park, Edifício 10, 2740-271 Porto Salvo, Portugal
NIPC/Matriculada na Conservatória do Registo Comercial de Cascais sob o nº 500 162 166
Capital Social 7.346.687,82 Euros
www.pfizer.pt
Apoio:
CARCINOMA
DE
HOTEL
TIVOLI ALMANSOR
19 DE ABRIL DE 2015
Prof. Michael Staehler
University of Munich,
Dept. of Urology, Germany
II CURSO
9:30
9:45
Boas Vindas/ Welcome
Prof. Dr. Arnaldo Figueiredo,
Dra. Gabriela Sousa
9:45
12:00
Targeted Agents: How can we better
use the best available options in firstand second-lines?
Discussão baseada em casos clínicos/
Clinical cases discussion
Prof. Dr. Michael Staehler,
Prof. Dr. Arnaldo Figueiredo,
Dra. Gabriela Sousa
12:00
12:30
Conclusão e encerramento/
Closing remarks
Prof. Dr. Arnaldo Figueiredo,
Dra. Gabriela Sousa
Michael Staehler is the Head of the Interdisciplinary Centre for Renal Tumors
and vice chairmen of the department of urology at the Ludwig-Maximilians
University of Munich, Germany. He also is consultant to the Interdisciplinary
Tuberous Sclerosis Centre of the LMU. He was head of the German Society for
Immune- and Targeted Therapy and is Member of the Renal Cancer Workgroup
of the German Cancer Society. He also serves as a member of the European
Association of urology and German Guideline Committee on Renal Cancer.
Following medical qualification at University of Munich Medical School and
gaining experience in general, vascular and thoracic surgery at the University of
Regensburg, the University of California in San Francisco and his training in
Urology at the Free University, Berlin, he was awarded a PhD for his work on renal
cancer at the University of Munich. After joining the Department of Urology, he
was appointed Consultant Urologist at Grosshadern Clinics and founded the
Interdisciplinary Centre on Renal Tumors in Germany. He is also Head of the
Urological Oncology Service for Advanced Genitourinary Cancer and Kidney
surgery. He is a Medical Advisor to the German Kidney Cancer Association. On
the editorial board of several journals, Professor Staehler has published more
than 70 articles on renal cancer and co-authored six textbooks.